C
CHARM Therapeutics
Biotech & Life Sciences · London, United Kingdom · Founded 2021
Uses deep learning on 3D molecular configurations to develop molecule therapeutics to target pathogenic proteins MoreLess
A 3D deep-learning research company that discovers and develops medicines for diseases such as cancer.
CHARM Therapeutics utilizes its proprietary DragonFold platform, which is based on protein-ligand co-folding, to identify novel molecules for drug discovery. The company has a strategic focus on creating small-molecule drugs. The business model appears to be centered on leveraging its advanced AI-driven technology to accelerate the drug discovery process, potentially entering into collaborations and partnerships with larger pharmaceutical companies, as evidenced by their collaboration with Bristol Myers Squibb. The company has raised a total of $70 million in funding to date, which supports its research and development activities. The primary clients and beneficiaries of CHARM's work would be patients in need of new treatments, and their partners in the pharmaceutical industry.
Keywords: 3D deep-learning, drug discovery, oncology, small-molecule drugs, protein-ligand co-folding, DragonFold, pharmaceutical collaborations, medical research, biotechnology, computational chemistry
Company overview
CHARM Therapeutics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2021
- Headquarters
- London, United Kingdom
- Employees
- 33
- Open positions
- None listed
- Dealroom signal
- 63.1
Valuation & funding
CHARM Therapeutics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | Sep 2025 | $80M | $320M | Nvidia · Khosla Ventures · OrbiMed · NEA | ↗ |
| EARLY VCOther financing | Apr 2023 | $20M | $80M | NVentures | ↗ |
| SERIES AOther financing | Jun 2022 | $50M | $200M | General Catalyst · Khosla Ventures · Bravos Capital · Axial VC | ↗ |
| EARLY VCOther financing | Oct 2021 | $13M | $50M | Undisclosed | ↗ |
Financials
Revenue and workforce over time
Available revenue and workforce history. Fields without reported data are omitted.
| Year | Revenue | Growth | Employees |
|---|---|---|---|
| 2026 | $7.3M | 0% | 33 |
| 2025 | $7.3M | 0% | 37 |
| 2024 | $7.3M | 0% | 62 |
| 2023 | $7.3M | +168.5% | 57 |
| 2022 | $2.7M | — | 41 |
Growth signals
CHARM Therapeutics website traffic
Latest recorded traffic for CHARM Therapeutics is 6.1K monthly website visits, up 13% over the last three months. CHARM Therapeutics's team declined 10.8% over the past year.
Comparisons
CHARM Therapeutics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
CHARM Therapeutics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where CHARM Therapeutics has talent and traffic
team presence
In the news
Latest news about CHARM Therapeutics
Recent press, funding announcements, and product moves mentioning CHARM Therapeutics — open to read from the original sources.
Market sentiment
What the market is saying about CHARM Therapeutics
An AI-synthesized read of the highest-engagement posts about CHARM Therapeutics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See CHARM Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.